Aktis Oncology (AKTS) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

Aktis Oncology Inc (AKTS) Prix de l'Action, Cotation, Actualités et Historique

AKTSNASDAQ

Trade with Public

Trade with Public

$15.12

0.060.4%

Dern. MÀJ: Oct 16, 4:00 PM

$15.12

0.060.4%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

$15.19

Clôture

-

Volume / Moy.

149.98K / 360.23K

Fourchette Journalière

$14.84 - $15.32

Plage 52 Sem.

14.72 - 34.19

Capitalisation Boursière

$840.97M

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

21

Intérêt à Découvert

29.16%

Jours pour Couvrir

7.3

Actualités Récentes de Aktis Oncology Inc

Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs

Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.

Piero Cingari

DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday

US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.

Avi Kapoor

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, visit analyst ratings page. Consider buying AKTS stock? Analysts weigh in.

Avi Kapoor

Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday

U.S. stocks were mixed, with the Dow Jones gaining 100 points. Rezolve AI (RZLV) jumped 11.9%, and other stocks such as ALOY and FWRD also rose.

Avi Kapoor

This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday

Top analysts change outlook on Hyperfine Inc, Legence, and Aktis Oncology with Buy/Outperform ratings and price targets. See other analysts' views.

Avi Kapoor

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

-75.29M

Flux de Trésorerie d'Investissement (TTM)

-289.39M

Flux de Trésorerie de Financement (TTM)

336.96M

Flux de Trésorerie Libre (TTM)

-84.57M

Dépenses en Capital (TTM)

-9.27M

Variation Nette de la Trésorerie (TTM)

-27.72M

Tendances et prévisions des analystes

1

juil.

2

août

1

sept.

1

oct.

Acheter

Conserver

Vendre

Vente forte

Évaluation et prévisions des analystes

4.4

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

$330.99M

Ratio P/E (TTM)

-

Ratio P/E (FWD)

-

Ratio PEG (TTM)

-

Ratio P/S (TTM)

82.76

Ratio P/B (TTM)

1.73

Rendement des Bénéfices % (TTM)

-8.79%

Rendement des Bénéfices % (FWD)

-17.61%

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

-

Valeur Comptable / Action

$8.72

Dette Entreprise

Dette Totale

-

Dette à Long Terme

-

Émission de Dette à Long Terme (TTM)

-

Remboursement de la Dette à Long Terme (TTM)

-

Trésorerie Totale

$82.49M

Dette sur Capitaux Propres

0.02

Émission de Dette (TTM)

-

Remboursement de la Dette (TTM)

-